Who
Paul D. Rubin
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, BioAge Labs; EVP, Research & Development, Viridian Therapeutics; Sr. VP Clinical Dev. & CMO, Xoma; President and CEO, Critical Therapeutics.
In numbers
- Trades disclosed
- 211
- Buys
- 0
- Sells
- 42
- Bought
- $0
- Sold
- $3.2M
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 3 Jan 2006
- Last trade
- 1 Apr 2026
- Last filed
- 3 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Apr 2026filed 3 Apr 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $22K5,437 at $4.11 | filing |
| 1 Apr 2026filed 3 Apr 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $22K3,383 at $6.57 | filing |
| 1 Apr 2026filed 3 Apr 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Sold | $157K8,820 at $17.81 | filing |
| 1 Apr 2026filed 3 Apr 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,437 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,383 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,437 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,383 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $22K5,437 at $4.11 | filing |
| 1 Apr 2026filed 3 Apr 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $22K3,383 at $6.57 | filing |
| 1 Apr 2026filed 3 Apr 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Sold | $157K8,820 at $17.81 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $22K5,433 at $4.11 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $13K2,000 at $6.57 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Sold | $151K7,433 at $20.30 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,433 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,433 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $22K5,433 at $4.11 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Code M | $13K2,000 at $6.57 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Sold | $151K7,433 at $20.30 | filing |
News
BioAge Labs (NASDAQ:BIOA) & GSK (NYSE:GSK) Head-To-Head AnalysisBIOA · themarketsdaily.com · 16 Oct 2026
0 headlines in the last 90 days name Paul D. Rubin; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.